Highway to heal: Influence of altered extracellular matrix on infiltrating immune cells during acute and chronic lung diseases

Mugdha M. Joglekar*, Mehmet Nizamoglu, YiWen Fan, Sai Sneha Priya Nemani, Markus Weckmann, Simon D. Pouwels, Irene H. Heijink, Barbro N. Melgert, Janesh Pillay, Janette K. Burgess

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

21 Downloads (Pure)

Abstract

Environmental insults including respiratory infections, in combination with genetic predisposition, may lead to lung diseases such as chronic obstructive pulmonary disease, lung fibrosis, asthma, and acute respiratory distress syndrome. Common characteristics of these diseases are infiltration and activation of inflammatory cells and abnormal extracellular matrix (ECM) turnover, leading to tissue damage and impairments in lung function. The ECM provides three-dimensional (3D) architectural support to the lung and crucial biochemical and biophysical cues to the cells, directing cellular processes. As immune cells travel to reach any site of injury, they encounter the composition and various mechanical features of the ECM. Emerging evidence demonstrates the crucial role played by the local environment in recruiting immune cells and their function in lung diseases. Moreover, recent developments in the field have elucidated considerable differences in responses of immune cells in two-dimensional versus 3D modeling systems. Examining the effect of individual parameters of the ECM to study their effect independently and collectively in a 3D microenvironment will help in better understanding disease pathobiology. In this article, we discuss the importance of investigating cellular migration and recent advances in this field. Moreover, we summarize changes in the ECM in lung diseases and the potential impacts on infiltrating immune cell migration in these diseases. There has been compelling progress in this field that encourages further developments, such as advanced in vitro 3D modeling using native ECM-based models, patient-derived materials, and bioprinting. We conclude with an overview of these state-of-the-art methodologies, followed by a discussion on developing novel and innovative models and the practical challenges envisaged in implementing and utilizing these systems.
Original languageEnglish
Article number995051
Number of pages13
JournalFrontiers in Pharmacology
Volume13
DOIs
Publication statusPublished - 3-Nov-2022

Cite this